Barclays PLC Altimmune, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Altimmune, Inc. stock. As of the latest transaction made, Barclays PLC holds 155,741 shares of ALT stock, worth $1.28 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

155,741

Previous 155,741 -0.0%

Holding current value

$1.28 Million

Previous $956,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$5.5 - $8.1 $412,852 - $608,018	75,064 Added 93.04%	155,741 $956,000
Q2 2024 Aug 14, 2024	SELL	$5.91 - $10.23 $116,296 - $201,305	-19,678 Reduced 19.61%	80,677 $535,000
Q1 2024 May 15, 2024	BUY	$8.22 - $13.81 $229,601 - $385,740	27,932 Added 38.57%	100,355 $1.02 Million
Q4 2023 Feb 15, 2024	SELL	$2.14 - $11.62 $231,090 - $1.25 Million	-107,986 Reduced 59.86%	72,423 $814,000
Q3 2023 Nov 07, 2023	BUY	$2.4 - $3.45 $165,633 - $238,098	69,014 Added 61.95%	180,409 $470,000
Q2 2023 Aug 03, 2023	SELL	$3.45 - $5.97 $398,357 - $689,332	-115,466 Reduced 50.9%	111,395 $394,000
Q1 2023 May 04, 2023	SELL	$4.19 - $16.83 $563,052 - $2.26 Million	-134,380 Reduced 37.2%	226,861 $957,000
Q4 2022 Feb 13, 2023	BUY	$8.74 - $16.45 $1.51 Million - $2.85 Million	173,277 Added 92.19%	361,241 $5.94 Million
Q3 2022 Nov 03, 2022	SELL	$10.67 - $22.41 $9.36 Million - $19.7 Million	-877,583 Reduced 82.36%	187,964 $2.4 Million
Q2 2022 Aug 12, 2022	SELL	$3.94 - $11.77 $353,551 - $1.06 Million	-89,734 Reduced 7.77%	1,065,547 $12.5 Million
Q1 2022 May 16, 2022	BUY	$5.9 - $9.45 $355,303 - $569,088	60,221 Added 5.5%	1,155,281 $7.04 Million
Q4 2021 Feb 14, 2022	BUY	$8.69 - $12.48 $7.06 Million - $10.1 Million	812,041 Added 286.92%	1,095,060 $10 Million
Q3 2021 Nov 09, 2021	BUY	$8.43 - $16.81 $1.81 Million - $3.61 Million	215,047 Added 316.38%	283,019 $3.2 Million
Q2 2021 Aug 13, 2021	BUY	$9.85 - $16.46 $346,000 - $578,190	35,127 Added 106.95%	67,972 $670,000
Q1 2021 May 13, 2021	BUY	$12.71 - $24.31 $57,766 - $110,488	4,545 Added 16.06%	32,845 $464,000
Q4 2020 Feb 11, 2021	BUY	$7.84 - $14.22 $784 - $1,422	100 Added 0.35%	28,300 $319,000
Q3 2020 Nov 12, 2020	SELL	$9.93 - $33.26 $908,743 - $3.04 Million	-91,515 Reduced 76.44%	28,200 $372,000
Q2 2020 Aug 12, 2020	BUY	$2.9 - $10.71 $347,173 - $1.28 Million	119,715 New	119,715 $1.28 Million

Others Institutions Holding ALT

# of Institutions

186

Shares Held

39.3M

Call Options Held

913K

Put Options Held

743K

View Full List

About Altimmune, Inc.

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $404M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

More about ALT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account